PARTNER NEWS:Thu, May 9, 10:40 AM, Zacks
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
Editas (EDIT) reports weaker-than-expected first-quarter 2024 results as both earnings and revenues fall shy of estimates. Shares fall.
Thu, May 9, 8:58 AM, Zacks
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.